Age, pathology and CA-125 are prognostic factors for survival in patients with brain metastases from gynaecological tumours

Andrews, 2004, Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial, Lancet (London, England), 363, 1665, 10.1016/S0140-6736(04)16250-8 Hasegawa, 2003, Brain Metastases Treated with Radiosurgery Alone: An Alternative to Whole Brain Radiotherapy?, Neurosurgery, 52, 1318, 10.1227/01.NEU.0000064569.18914.DE Nayak, 2012, Epidemiology of brain metastases, Curr Oncol Rep, 14, 48, 10.1007/s11912-011-0203-y Berghoff, 2016, Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers, ESMO Open, 1, 10.1136/esmoopen-2015-000024 Cagney, 2017, Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study, Neuro Oncol, 19, 1511, 10.1093/neuonc/nox077 Nasu, 2013, Clinicopathologic features of brain metastases from gynecologic malignancies: A retrospective study of 139 cases (KCOG-G1001s trial), Gynecol Oncol, 128, 198, 10.1016/j.ygyno.2012.11.001 Hacker, 2016, Surgical management of lung, liver and brain metastases from gynecological cancers: a literature review, Gynecol Oncol Res Pract, 3, 7, 10.1186/s40661-016-0028-3 Rades, 2017, A new scoring tool to assess overall survival in patients with intracerebral metastases from gynecological cancers, Int J Gynecol Cancer, 27, 597, 10.1097/IGC.0000000000000899 Janssen, 2018, An instrument for estimating the 6-month survival probability after whole-brain irradiation alone for cerebral metastases from gynecological cancer, Anticancer Res, 38, 3753, 10.21873/anticanres.12656 Gilani, 2016, Brain metastases in patients with gynecologic cancers: a single institution experience and review of the literature, Open J Obstet Gynecol, 06, 544, 10.4236/ojog.2016.69070 Seute, 2008, Detection of brain metastases from small cell lung cancer: consequences of changing imaging techniques (CT versus MRI), Cancer, 112, 1827, 10.1002/cncr.23361 Pope, 2018, Brain metastases: neuroimaging, Handb Clin Neurol, 149, 89, 10.1016/B978-0-12-811161-1.00007-4 Gaspar, 1997, Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials, Int J Radiat Oncol, 37, 745, 10.1016/S0360-3016(96)00619-0 Sperduto, 2012, Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases, J Clin Oncol, 30, 419, 10.1200/JCO.2011.38.0527 Sterne, 2009, Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls, BMJ, 338, 10.1136/bmj.b2393 Moons, 2006, Using the outcome for imputation of missing predictor values was preferred, J Clin Epidemiol, 59, 1092, 10.1016/j.jclinepi.2006.01.009 Landelijke richtlijn hersenmetastasen, versie 3.0. Landelijke werkgroep neuro-oncologie. oncoline.nl. Published 2011. Core, 2017, A language and environment for statistical computing, R Found Stat Comput Marchetti, 2016, Brain metastases in patients with EOC: Clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19), Gynecol Oncol, 143, 532, 10.1016/j.ygyno.2016.09.025 Matsunaga, 2016, Gamma knife surgery for metastatic brain tumors from gynecologic cancer, World Neurosurg, 89, 455, 10.1016/j.wneu.2016.01.062 Johnston, 2017, Stereotactic radiosurgery in the treatment of brain metastases from gynecologic primary cancer, J Radiosurg SBRT, 5, 55 Anupol, 2002, Evaluation of prognostic factors and treatment modalities in ovarian cancer patients with brain metastases, Gynecol Oncol, 85, 487, 10.1006/gyno.2002.6653 Piura, 2011, Brain metastases from ovarian carcinoma, ISRN Oncol, 2011, 1, 10.5402/2011/527453 Dodge, 2012, Preoperative identification of a suspicious adnexal mass: a systematic review and meta-analysis, Gynecol Oncol, 126, 157, 10.1016/j.ygyno.2012.03.048 Henderson, 2018, Screening for ovarian cancer, JAMA, 319, 595, 10.1001/jama.2017.21421 Johnson, 2008, The epidemiology of CA-125 in women without evidence of ovarian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial, Gynecol Oncol, 110, 383, 10.1016/j.ygyno.2008.05.006 Masahashi, 1988, Serum CA 125 levels in patients with endometriosis: changes in CA 125 levels during menstruation, Obstet Gynecol, 72, 328 Bottoni P, Scatena R. The role of CA 125 as tumor marker: biochemical and clinical aspects. In: ; 2015:229-244. doi:10.1007/978-94-017-7215-0_14. Gupta, 2009, Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature, J Ovarian Res, 2, 13, 10.1186/1757-2215-2-13 Clarke, 2014, Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment, Cochrane Database Syst Rev, CD006119 Rustin, 2010, Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial, Lancet, 376, 1155, 10.1016/S0140-6736(10)61268-8 Netherlands Comprehensive Cancer Organization Netherlands Cancer Registry. www.cijfersoverkanker.nl. Published 2019. Yamamoto, 2014, Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study, Lancet Oncol, 15, 387, 10.1016/S1470-2045(14)70061-0